The Onso Sequencing System is Designed to
Deliver Industry-Leading Sensitivity and Specificity for Novel
Insights in Oncology and Disease Research
MENLO
PARK, Calif., Oct. 25,
2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced the commencement of external beta
testing of the Onso™ sequencing system. This innovative
benchtop short-read DNA sequencing platform is expected to provide
an extraordinary level of accuracy by utilizing PacBio's unique
sequencing by binding (SBB) technology.
"We are excited to see how researchers will leverage the
ground-breaking sequencing accuracy that we expect Onso to deliver.
Upon the launch, we expect to become the only company that we know
of to offer both highly accurate, native short- and long-read
sequencing technologies, which will enable us to offer more
complete solutions to our customers' challenges," said Christian Henry, President and Chief Executive
Officer of PacBio. "Onso is designed to deliver highly accurate
sequencing reads, support scalable, flexible, and cost-optimized
operation, and enable customers to feel more confident in their
science. This system is designed to be a game changer for the
genomics industry, and we're excited to begin shipping beta systems
to our beta partners."
PacBio expects to begin taking orders for Onso in the first
quarter of 2023 and expects to begin shipments of the system in the
first half of 2023 upon completion of the external beta program.
PacBio has chosen three beta testing sites for Onso: The Broad
Institute of MIT and Harvard, Corteva Agriscience, and Weill Cornell
Medicine. Through the beta testing, scientists will be able to test
Onso's specifications and provide critical feedback to PacBio.
Onso has been designed for compatibility with the rich ecosystem
of products currently available for short-read sequencers. It
supports a diverse set of library preparation types, single-cell
analysis solutions, and whole-genome sequencing and other targeted
methods, such as amplicon and hybridization capture panels. It is
anticipated to deliver 500 million reads per run and offer 200 and
300 cycle kits enabling paired- and single-end reads, at a list
price of US $259,000 per system.
"We believe the differentiated accuracy and workflow will allow
scientists to process many more samples with the same output as
other on-market short-read sequencing platforms," said Mark Van Oene, Chief Operations Officer at
PacBio. "Onso is expected to bring a new standard of data quality
and efficiency that allows for better interrogation of the genome
without over-sequencing and complicated error correction methods.
In oncology research applications, we are excited to demonstrate
Onso's extraordinary sensitivity and specificity for studying
genetic variants and for advancing the development of diagnostic
tools to improve therapy selection and recurrence
monitoring."
"We are excited to see continued innovation in the sequencing
technology landscape," says Stacey
Gabriel, Chief Genomics Officer and Senior Director of the
Genomics Platform at the Broad Institute of MIT and Harvard.
"Improved accuracy and the ability to call challenging variants
will be particularly important as we continue to refine targeted
areas of the genome that harbor actionable and other clinically
relevant variants."
"The high accuracy of the new Onso system from PacBio opens new
opportunities for agricultural biotechnology," said Gina Zastrow-Hayes, Biotechnology and
GT-Genomics Technology Manager at Corteva Agriscience. "We look
forward to bringing the technology in-house and applying it to
applications such as gene editing specificity analysis that can
benefit from increased accuracy."
PacBio has also posted a presentation to its website with
additional details about Onso. Interested parties can access the
presentation on PacBio's Investor Relations website, here and
product information here.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a
premier life science technology company that is designing,
developing and manufacturing advanced sequencing solutions to help
scientists and clinical researchers resolve genetically complex
problems. Our products and technology under development stem from
two highly differentiated core technologies focused on accuracy,
quality and completeness which include our existing HiFi long read
sequencing and our emerging SBB™ short read sequencing
technologies. Our products address solutions across a broad set of
research applications including human germline sequencing, plant
and animal sciences, infectious disease and microbiology, oncology,
and other emerging applications. For more information please
visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use
in diagnostic procedures.
Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and the U.S. Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical fact
are forward-looking statements, including statements relating to
future availability, uses, accuracy, advantages, quality or
performance of, or benefits or expected benefits of using, PacBio
products or technologies, including the Onso sequencing system;
expected levels of accuracy, sensitivity, and specificity;
expectations that PacBio will be the only company to offer short-
and long-read sequencing technologies; expected scalability,
flexibility and cost optimization of Onso; expected compatibility
of Onso with products currently available for short-read sequencers
and ability to support diverse library preparation types, single
cell analysis solutions, whole-genome sequencing and other targeted
methods; anticipated number of reads per run and cycle flow cells;
anticipated pricing; expected ability to process more samples with
the same output as other commercially available platforms;
expectations regarding data quality and efficiency in connection
with genome interrogation; expected use in oncology research and
agricultural biotechnology applications; expectations with respect
to continue development and delivery timeframes, and other future
events. Readers are cautioned not to place undue reliance on these
forward-looking statements and any such forward-looking statements
are qualified in their entirety by reference to the following
cautionary statements. All forward-looking statements speak only as
of the date of this press release and are based on current
expectations and involve a number of assumptions, risks and
uncertainties that could cause the actual results to differ
materially from such forward-looking statements, including, among
others, challenges inherent in developing, manufacturing,
launching, marketing and selling new products, and achieving
anticipated new sales; Onso is entering beta testing, is not yet
commercially available, and remains subject to additional
development and validation; potential product performance and
quality issues and potential delays in development timelines;
assumptions, risks and uncertainties related to the ability to
attract new customers and retain and grow sales from existing
customers; rapidly changing technologies and extensive competition
in genomic sequencing that could make the products PacBio is
developing obsolete or non-competitive; supply chain risks;
successfully completing development of a product that is not yet
commercially available; customers and prospective customers
curtailing or suspending activities utilizing our products; the
impact of U.S. export restrictions on the shipment of PacBio
products to certain countries; and third-party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate PacBio's patents or proprietary rights. Readers are
strongly encouraged to read the full cautionary statements
contained in PacBio's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Forms
8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or
revise any forward-looking statements.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-onso-the-highly-accurate-short-read-sequencing-platform-301658659.html
SOURCE Pacific Biosciences of California, Inc.